DO
Dwight Owen
The Ohio State University
Research areas: Medicine · Pulmonary and Respiratory Medicine · Lung Cancer Treatments and Mutations · Cancer Immunotherapy and Biomarkers · Lung Cancer Diagnosis and Treatment
0000-0002-6598-4886
Employment
Employment history is unavailable.
Education
-
Ohio State University M.S.c2014 - 2017
Projects & Funding
Projects & funding information is unavailable.
Publications (35)
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3 Save
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.3 Save
- Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial Save
- Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells Save
- Treatment of Non–Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency Save
- Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Save
- Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Save
- Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. Save
- <p>Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers</p> Save
- Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Save
- DLL3: an emerging target in small cell lung cancer Save
- Reply to J. Delyon et al. Save
- Metastatic Adrenocortical Carcinoma: a Single Institutional Experience. Save
- Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer Save
- Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. Save
- Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Save
- KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer. Save
- Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors? Save
- Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. Save
- Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. Save